Trump’s budget plan puts squeeze on NIH, boosts FDA
March 12, 2019
By Neozene

President Trump’s budget proposals for 2020 are in, seeking a cut for the National Institutes of Health (NIH) for the third year in a row but an increase in the FDA’s finances. The plan is allocating $35.4 billion for the NIH—estimated to be somewhere between $4.5 and $6 billion less than in the current financial year—and is accompanied by other cuts including a $1 billion reduction for the National Science Foundation (NSF). Among the biggest losers within the NIH are the National Cancer Institute, which would see $900 million carved

Read More

Preventing Unnecessary Exposure to Opioids After Surgery
February 19, 2019
By Neozene

It’s nearly impossible to pick up a newspaper or scroll through Twitter without coming across a story about the misuse of and addiction to opioids.  These include prescription pain relievers, heroin, and synthetic opioids such as fentanyl. With 130 people dying of an overdose every day, it has become our country’s greatest health crisis since the AIDS epidemic of the 80s and 90s…an epidemic that can affect anyone regardless of age, culture, education or socio-economic status. More than 650,000 opioid prescriptions are dispensed on an average day, according to the

Read More

J&J’s Nasal Antidepressant Heads for FDA Panel
February 12, 2019
By Neozene

Johnson & Johnson’s new antidepressant esketamine comes in front of an FDA advisory committee tomorrow, hoping to end a drought in novel therapies for the disorder. There has been a lot of debate about the likely outcome of the meeting given that not all of J&J’s studies support the intranasally administered drug, but analysts at Credit Suisse think that the FDA is “supportive of approval” based on published briefing documents. If approved by the FDA, esketamine would become one of the first new approaches to treat refractory major depressive disorder (MDD)

Read More